The interplay between the immune system and tumor progression is well recognized. However, 35 current human breast cancer immunophenotyping studies are mostly focused on primary tumors 36 with metastatic breast cancer lesions remaining largely understudied. To address this gap, we 37 examined exome-capture RNA sequencing data from 50 primary breast tumors (PBTs) and their 38 patient-matched metastatic tumors (METs) in brain, ovary, bone and gastrointestinal tract. We 39 used gene expression signatures as surrogates for tumor infiltrating lymphocytes (TIL) and 40 compared TIL patterns in PBTs and METs. Enrichment analysis and deconvolution methods 41 both revealed that METs have a significantly lower abundance of total immune cells, including 42 CD8+ T cells, regulatory T cells and dendritic cells. An exception was M2-like macrophages, 43 which were significantly higher in METs across the organ sites examined. Multiplex 44 immunohistochemistry results were consistent with data from the in-silico analysis and showed 45 increased macrophages in METs. We confirmed the finding of a significant reduction in immune 46 cells in brain (BRM) METs by pathologic assessment of TILs in a set of 49 patient-matched 47 pairs of PBT/BRMs . These findings indicate that METs have an overall lower infiltration of 48 immune cells relative to their matched PBTs, possibly due to immune escape. RNAseq analysis 49 suggests that the relative levels of M2-like macrophages are increased in METs, and their 50 potential role in promoting breast cancer metastasis warrants further study. 51 52 Inform software (18). The list of antibodies with catalog numbers and dilutions used provided in 129 supplementary
Introduction 53
Breast cancer is a highly heterogenous disease affecting 1 in 8 women in the US, and the most 54 commonly diagnosed cancer in women worldwide. Despite recent improvements in overall 55 survival rates, it is still the second leading cause of mortality due to cancer in women (1). In the 56 last two decades, significant progress has been made in the detection and treatment of primary 57 breast tumors as a result of enhanced understanding of disease biology and the tumor 58 microenvironment (TME). The breast TME represents a complex interaction between tumor 59 cells, endothelial cells, fibroblasts, and a variety of pro-and anti-tumor immune cells capable of 60 tipping tumor biology toward tumor growth and progression or immune rejection. During tumor 61 growth, cancer cells can be detected and eliminated by the immune system, but some cancer cells 62 may exploit several mechanisms to evade destruction by the immune system, enabling them to 63 escape immune surveillance and progress through the metastatic cascade. For breast cancer, the 64 most common sites of distant organ metastases include bones, lungs, liver and brain with ovaries 65 and gastrointestinal tract being affected less frequently (2). 66
67
The interplay between the immune system and tumor development is now well recognized in a 68 variety of tumor types, including the triple negative (TNBC) and HER2+ subtypes of breast 69 cancer (3, 4) . However, existing immunophenotyping studies focus mainly on primary tumors, 70 with the role of immune cells in metastatic progression remaining largely understudied. While 71 numerous studies have now documented cellular and genomic evolution of breast cancers during 72 metastasis (5, 6), very little is known about the co-evolution of immune cells and the TME. This 73 study focused on addressing this gap in our understanding by performing immunophenotyping 74 on two datasets: a) Pan-MET, transcriptomic profiles of 50 pairs of patient-matched primary 75 (PBTs) and metastatic breast tumors (METs) in brain (BRM), ovary (OVM), bone (BOM) and 76 gastrointestinal tract (GIM); and b) BRM-sTIL, a multi-institutional cohort of 49 patient-77 matched pairs of PBTs and BRMs with stromal tumor infiltrating lymphocytes (sTILs) 78 percentages evaluated by pathologic evaluation of hematoxylin & eosin (H&E) staining. Using 79 gene expression signatures as surrogates for TILs, we discovered quantitative differences in 80 immune cell profiles between PBTs and METs in the first dataset (Pan-MET). Those differences 81 were confirmed using multiplexed immunofluoresence (mIF) in three pairs of PBT/OVMs and 82 PBT/BRMs each. Consistent results were observed by comparing the sTILs percentages in 83 additional PBT/BRM pairs in a second dataset (BRM-sTIL). Higher immune cell recruitment to 84 the TME was also confirmed to be associated with better survival in both datasets. Our study 85 demonstrates the potential of using bioinformatics tools to investigate the evolution of the 86 immune TME in breast cancer metastasis, and identifies M2-like macrophages as a potential 87 therapeutic target for metastatic breast cancer. (Table S4) . 105
Materials and Methods

106
Immune abundance quantification of samples in Pan-MET dataset 107
Total immune single-sample gene set enrichment analysis (ssGSEA) score and tumor purity were 108 calculated using R package ESTIMATE (10). Abundance of each immune cell population were 109 calculated by R package GSVA (11) based on two sets of immune gene signatures, Davoli 110 signatures (12) and Tamborero signatures (13) . We also applied two deconvolution methods, 111 CIBERSORT (14) and TIMER (15) . All four methods were tested on a single cell RNA-seq dataset of 11 breast cancer tumors (16 subjected to cycles of antigen retrieval, blocking, primary antibody followed by secondary-HRP 125 antibody. Separate Opal detection and signal amplification antibodies were used for each marker. 126
The panel of markers used included CD8, CD20, CD68, Foxp3, PD-L1, pan-CK and DAPI. 127
Imaging, analysis and quantification was performed using the Perkin Elmer Vectra platform and 128 counted. Full tumor sections were preferentially examined over needle biopsies whenever 137 possible; core biopsies were analyzed when full sections were unavailable. Each slide was 138 independently reviewed by two study personnel (JLN and CL) We estimated total immune abundance using RNAseq from 50 pairs of patient-matched PBTs 152 and METs. METs showed a significantly lower total immune ssGSEA score compared to 153 patient-matched PBTs ( Fig 1A; p<0 .001). To minimize the potential bias of tumor cellularity, we 154 also compared the normalized ssGSEA immune scores which were divided by the percentage of 155 non-tumor content, as higher tumor purity naturally indicates lower immune abundance. Since 156 such normalization did not change the conclusion ( Fig S1A) , and considering this normalization 157 was an overly simplified approximation and did not differentiate tumor from stromal regions, we 158 used the immune ssGSEA score without normalization for further analysis to avoid introducing 159 additional bias. The decrease in immune score was observed in METs collected from various 160 sites, but was especially apparent in BRMs ( Fig 1B) . Validating this finding, pathologic 161 assessment of sTILs in an an additional cohort of 49 patient-matched PBTs and METs revealed 162 that BRMs also showed a significant decrease in the percentage of sTILs compared to patient-163 matched PBTs ( Fig 1C; p<0.001). When grouping PBT/MET pairs by hormone receptor status 164 (HR) and HER2 status, both datasets revealed a trend of decreased immune abundance in all 165 subtypes, with TNBC subtype having the most significant decrease ( Fig S1(B-C) ). While the 166 total immune ssGSEA score only estimates the overall immune abundance in the bulk sample 167 from RNAseq, and the sTILs percentage was carefully counted as the immune cell percentage in 168 the stroma, the two measurements of immune abundance were significantly (p< 0.001) correlated 169 for the 15 pairs of PBT/BRMs within both data sets ( Fig 1D) . 170 171 In addition, we also observed that METs had significantly lower expression of immune 172 checkpoint molecules that downregulate immune response -including CD274 (PD-L1), 173 PDCD1 (PD-1) and CTLA4 ( Fig S2) -possibly due to fewer total immune cells. Differential 174 expression (DE) test identified 1,659 up-regulated and 1,036 down-regulated genes in the 175 comparsion of ER+ BRMs versus PBTs under FDR 0.05 cutoff. Pathway enrichment analysis of 176 DE genes identified KEGG pathway "primary immunodeficiency" among the top 15 177 significantly enriched pathways, further confirming our previous findings (Table S3 ). 178 179 Taken together, both transcriptomic data and pathological assessment showed that METs have 180 lower immune abundance than patient-matched PBTs. 181
182
METs have higher percentage of M2-like macrophages relative to the total immune abundance 183
184
We inferred the abundance of each immune cell population by enrichment analysis and 185 deconvolution methods. To validate those approaches, we first compared the GSVA scores of 186 four common immune cell populations defined by both Davoli et al. (12) and Tamborero et al. 187 (13) . The correlations ranged from 0.4 to 0.85 ( Fig S3) , indicating overall high consistency. For 188 further validation, we applied four methods; namely GSVA using the immune signatures from 189
Davoli and Tomborero, and two methods of deconvolution (CIBERSORT and TIMER) to a 190 publicly available single cell RNA-seq dataset (16) but M2-like macrophages were significantly higher in METs ( Fig 2D) . Significant increment was 203 also observed in the ratio of the relative percentages of M2 and M1, indicating dominant level of 204 M2 over M1 (Fig 2E) . When separating PBT/MET pairs to different MET sites or HR/HER2 205 subtypes, the results were generally consistent ( Fig S5 and S6) . To further validate in silico results, we selected three pairs of PBT/BRMs and three pairs of 210 PBT/OVMs which were shown to have higher M2-like macrophages relative to the total immune 211 abundance. Multispectral immunofluorescence (mIF) was performed for the pairs (Fig 3A) . 212
Three pairs of PBT/OVMs and two pairs of PBT/BRMs showed increased macrophages in 213
METs, and the majority of METs had lower B cells and T cells ( Fig 3B) , consistent with 214 percentage estimated from CIBERSORT ( Fig 3C and Fig S7) . PBT/MET pairs into one cohort, immune ssGSEA score was not significantly associated with 230 MFS or SPM (Fig S8) , likely due to the confounding effect of different MET sites on outcome. 231
Considering PBT/BRM pairs had the largest sample size, we tested the potential association 232 between immune ssGSEA score and survival specifically in PBT/BRMs. In the pan-MET 233 dataset, there was a trend in association between higher immune levels in PBTs and longer time 234 to development of BRMs (i.e. MFS) ( Fig 4B) . However, such a trend was not observed between 235 SPM with immune levels in BRM or immune level change between PBT and BRM ( Fig 4B) . In 236 the BRM-sTIL dataset, higher sTILs percentage in PBT was not associated with MFS. Instead, 237 there was a trend toward an association between a higher sTILs percentage in MET and longer 238 SPM ( Fig 4C) . We did not observe significant associations between the relative level of M2-like 239 macrophage and survivals ( Fig S9) . 240 241
Discussion 242
It is now well appreciated that immune cells are a critical component of the TME. Studies of the 243 breast TME have largely focused on tumor mutational and transcriptional landscapes in primary 244 breast cancers, and with more recent attention to metastatic tumors. Our study is novel in two 245 main regards: (1) we examined two cohorts of matched PBTs and METs, one of which includes 246
METs in different sites, allowing us to discern site-specific immune changes from primary to 247 metastatic disease and (2) we evaluated immune abundance by both gene expression analysis and 248 H&E staining, and observed overall high consistency. Our data demonstrate the potential of 249 using bioinformatics tools to investigate the immune contexture of both primary and matched 250 metastatic tumors when tumor lesions may not be available for staining. 251 252 Our paired patient-matched comparison revealed a decrease in immune cells from primary to 253 metastatic breast cancer, which is consistent with limited existing studies (20) (21) (22) . In-silico 254 analysis of the Pan-MET dataset, validated by mIF staining, highlights the potential enrichment 255 of M2-like macrophages as the tumor cells metastasize to various sites, especially brain and 256 ovary. This is consistent with the growing body of literature that has shown macrophages to be 257 one of the key players in establishment of distant METs (23-25). Our survival analysis suggests 258 enhanced MFS and SPM in patients with higher immune cell recruitment to primary and 259 metastatic tumors, although the significance of these findings were not consistent between the Although we attempted to reduce such bias by normalizing the immune ssGSEA score against 271 the non-tumor cell percentage (with consistent conclusions), single cell RNA-sequencing may be 272 needed to completely resolve uncertainties related to cellular heterogeneity. Third, in our mIF 273 studies, the percentage of all immune cells within the tumor was often below 10%. Given these 274 limited numbers of immune cells, our results should be interpreted with caution. Despite these 275 limitations, our study clearly highlights an opportunity to utilize existing data to shed light on the 276 co-evolution and involvement of immune cells in the progression of a primary tumor and its 277 metastatic cascade within an individual patient. It also nominates M2-like macrophages as a 278 potential target for therapeutic immune manipulation of the metastatic cascade. 279
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